Trial Profile
A phase Ib study to evaluate NB 1001 in patients with type 2 diabetes
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 14 Oct 2015
Price :
$35
*
At a glance
- Drugs Vurolenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- 12 Oct 2015 Status changed from planning to active, no longer recruiting based on a Naia Limited media release.
- 09 Jan 2015 New trial record